Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SOMATOSTATIN AND SOMATOSTATIN RECEPTOR SUBTYPE GENE-EXPRESSION IN MEDULLARY-THYROID CARCINOMA
Autore:
MATO E; MATIASGUIU X; CHICO A; WEBB SM; CABEZAS R; BERNA L; DELEIVA A;
Indirizzi:
HOSP SANTA CRUZ & SAN PABLO,DEPT ENDOCRINOL,AV S ANTONI MACLARET 167 BARCELONA 08025 SPAIN UNIV AUTONOMA BARCELONA,HOSP SANTA CREU & ST PAU,DEPT ENDOCRINOL BARCELONA 08025 SPAIN UNIV AUTONOMA BARCELONA,HOSP SANTA CREU & ST PAU,DEPT PATHOL BARCELONA 08025 SPAIN UNIV AUTONOMA BARCELONA,HOSP SANTA CREU & ST PAU,DEPT NUCL MED BARCELONA 08025 SPAIN
Titolo Testata:
The Journal of clinical endocrinology and metabolism
fascicolo: 7, volume: 83, anno: 1998,
pagine: 2417 - 2420
SICI:
0021-972X(1998)83:7<2417:SASRSG>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
MOLECULAR-BIOLOGY; ANALOGS; CANCER; TUMORS; CELLS; ACID; PROLIFERATION; CLONING; TRACT; SSTR2;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
25
Recensione:
Indirizzi per estratti:
Citazione:
E. Mato et al., "SOMATOSTATIN AND SOMATOSTATIN RECEPTOR SUBTYPE GENE-EXPRESSION IN MEDULLARY-THYROID CARCINOMA", The Journal of clinical endocrinology and metabolism, 83(7), 1998, pp. 2417-2420

Abstract

The possible existence of an autocrine/paracrine role for SRIF in normal and neoplastic thyroid parafollicular C cells has supported the use of SRIF analogues in the treatment of patients with medullary thyroid carcinoma (MTC). In this study, we have investigated the expression of SRIF by immunohistochemistry and RT-PCR, and the expression of SRIFreceptor (SSTR) subtypes by RT-PCR, in a series of 14 MTCs. SRIF messenger RNA was detected in all cases, although immunoreactive cells were only identified in 8. SSTR messenger RNA was present in 12 out of the 14 tumors. Expression of more than 1 SSTR subtype was detected in 10tumors. SSTR2, the subtype that preferentially binds to the SRIF analogue octreotide, was the subtype most frequently detected, whereas SSTR4 was not detected in any case. These results confirm the frequent expression of both SRIF and its receptors in MTC. The presence of different combinations of SSTR subtypes in a given patient may explain the variable clinical response to SRIF analogues and may promote the searchfor more selective drugs with different affinities to the various receptor subtypes.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 01:34:02